Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Phase II Study of OSI-774 (Erlotinib, Tarceva) in Elderly Patients With Advanced Stage or Inoperable Non Small Cell Lung Cancer (NSCLC)

Authors not listed

Montefiore Medical Center · 2003

Abstract

The purpose of this research study is to determine if OSI-774 (Tarceva) is effective in the treatment of non-small cell lung cancer and to further study its side effects. The investigators would also like to estimate disease-related symptom improvement rates using a questionnaire.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-03 MST

Cite this

APA
Anonymous. (2003). Phase II Study of OSI-774 (Erlotinib, Tarceva) in Elderly Patients With Advanced Stage or Inoperable Non Small Cell Lung Cancer (NSCLC). <em>Montefiore Medical Center</em>. https://clinicaltrials.gov/study/NCT00200395
Vancouver
Anonymous. Phase II Study of OSI-774 (Erlotinib, Tarceva) in Elderly Patients With Advanced Stage or Inoperable Non Small Cell Lung Cancer (NSCLC). Montefiore Medical Center. 2003.
BibTeX
@misc{anon2003PhaseI, title = {Phase II Study of OSI-774 (Erlotinib, Tarceva) in Elderly Patients With Advanced Stage or Inoperable Non Small Cell Lung Cancer (NSCLC)}, author = {Anonymous}, journal = {Montefiore Medical Center}, year = {2003}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings